National

Govt Panel Approves India’s First Indigenously Developed Vaccine qHPV Against Cervical Cancer

Published on 17 Jun 2022

← Back to Current Affairs
  • The DCGI’s Subject Expert Committee recommends Serum Institute’s indigenously developed quadrivalent human papillomavirus (qHPV) vaccine for cervical cancer patients above 9 years to 26 years of age.
  • Cervical cancer in India ranks as the second most frequent cancer among women between 15 and 44 years of age.
  • Every year in India, 122,844 women are diagnosed with cervical cancer and 67,477 die from the disease.
  • The HPV vaccine reduces a woman’s risk of cervical cancer. Men cannot develop cervical cancer, but the HPV vaccine may prevent genital warts, penile cancer, anal cancer, and the spread of HPV to sexual partners.
Source: SarkariPariksha